(Reuters) -Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G" weight-loss drug candidate in a deal worth up to $2 billion.

The candidate at the center of the deal, dubbed UBT251, is a triple agonist for glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP) and glucagon. Wegovy already inhibits GLP-1 ...

UBT251 targets GLP-1, GIP, and a third hormone, glucagon, hence the name "triple G". Rival Eli Lilly (LLY.N), opens new tab is developing a similar drug, retatrutide, that has shown to help ...